Pharmacy Loans in Australia: How Lenders Really Assess a Community Pharmacy in 2026

Ask a business banker to name the small business they’d most like on their loan book and community pharmacy is usually near the top of the list. It’s not hard to see why: a large slice of a pharmacy’s income arrives via the Pharmaceutical Benefits Scheme, customers pay at the counter rather than on 60-day invoices, and demand for medicines doesn’t follow the economic cycle. Yet pharmacy is also one of the most heavily regulated businesses you can buy – the law dictates who may own one, how many they may own, and even influences where one can operate.

That combination – bankable income inside a tight regulatory frame – makes pharmacy finance its own discipline, quite different from generic small business lending. This guide looks at how lenders actually read a pharmacy in 2026: what the ownership rules mean for your loan structure, how the dispensary and the front of shop are assessed differently, and why the scope-of-practice changes rolling through every state are quietly reshaping what pharmacy owners borrow for. Mortgage & Finance Advisory (MFA) is based near Geelong and works with pharmacists and other professional clients Australia-wide by phone and video.

The Ownership Rules Come First – Before Any Talk of Money

Most business purchases start with the numbers. A pharmacy purchase starts with eligibility. Every Australian state and territory restricts pharmacy ownership to registered pharmacists, subject to narrow exceptions – in several states, certain friendly societies that were operating pharmacies decades ago retain grandfathered rights. A non-pharmacist investor cannot simply buy a pharmacy, and in general cannot take a proprietary interest in one either. That single fact shapes everything downstream: who the borrower can be, what entities can hold the business, and who is even in the market when a pharmacy changes hands.

The rules are state-based and they are not identical. Two examples our Victorian and interstate clients most often deal with:

For finance, three consequences follow. First, the borrowing entity must itself satisfy the ownership rules – a family trust or investor-backed company that would be routine in other industries may simply be impermissible here, which is why the entity conversation with your accountant has to happen before the loan application, not after. Second, outside capital can’t ride in on the equity side, so debt does more of the work in pharmacy transactions than in most business purchases. And third, the ownership caps mean the buyer pool for any pharmacy is finite – registered pharmacists who aren’t already at their limit – which is one reason well-run pharmacies rarely sit on the market for long.

Two Businesses Under One Roof: How Lenders Read the Numbers

A community pharmacy is really two businesses sharing a tenancy. Behind the counter sits the dispensary, whose income flows substantially from PBS-subsidised prescriptions – effectively a payment stream underpinned by the Commonwealth. In front of it sits a retail business selling everything from vitamins to skincare, which behaves like any other retail operation: exposed to foot traffic, competition and discretionary spending. Lenders read the two quite differently, and the split between them is one of the first things a credit analyst looks for in the financials.

The dispensary’s economics have been moving. The introduction of 60-day dispensing for many common medicines – phased in from September 2023 – meant fewer dispensing events for the same patients, and pharmacies felt it in script volumes. The Commonwealth’s response came through the Eighth Community Pharmacy Agreement, which commenced on 1 July 2024 and was reported at around $25 billion of funding for community pharmacy over five years, including changes to dispensing remuneration. The net effect differs pharmacy by pharmacy, which is precisely why lenders now dig into dispense-system reports – script numbers, government versus patient contributions, services income – rather than taking the top line at face value. A pharmacy that can show stable or growing scripts plus a genuine services stream presents far better than one relying on retail margin to paper over a shrinking dispensary.

Location is the third leg. A pharmacy’s ability to dispense PBS medicines attaches to approved premises, and long-standing location rules restrict where new PBS-approved pharmacies can open. Those rules are periodically reviewed, but their practical effect has been consistent: an established, PBS-approved pharmacy in a good catchment enjoys a degree of protection from new competition that almost no other retail business gets – and that scarcity is a large part of why pharmacy goodwill holds its value, and why lenders are prepared to lend against it. Where the freehold is also for sale, that’s usually financed as a separate facility – see our commercial property loans guide for how those are assessed.

Goodwill Lending: What ‘Borrowing Against the Pharmacy’ Actually Means

Because pharmacy income is unusually predictable, a group of lenders – including the health-specialist arms of major banks and dedicated healthcare financiers – will lend against the value of the pharmacy business itself, goodwill included, rather than requiring bricks-and-mortar security for every dollar. How far they’ll go depends on the pharmacy’s earnings quality, the price relative to valuation, your experience, and the lender’s current appetite: some transactions are funded substantially against the business alone, while others are strengthened with residential or commercial property security to improve the terms or bridge a deposit gap. No two lenders draw those lines in the same place, and published maximums shift – treat any specific percentage you read online as a starting point for a conversation, not a promise.

What every lender will do is test serviceability conservatively: can the pharmacy pay award wages (including a market wage for you), rent, stock and the proposed debt from its demonstrated cashflow, with a buffer? They’ll also look at the lease with unusual care – a pharmacy’s PBS approval attaches to its premises, so a short lease with no options is a genuine credit problem, not a technicality. And they’ll expect stock and fit-out to be dealt with sensibly: stock is often funded through a working capital facility sized to the pharmacy’s turnover (our cashflow and working capital guide covers the options), while dispensary robots, refrigeration and point-of-sale systems suit equipment finance secured against the asset itself.

First Pharmacy, Partnership Buy-In, or Refit: Three Different Conversations

Buying your first pharmacy is the classic path: an employed pharmacist or pharmacist-in-charge acquires an established pharmacy outright. The lender’s file looks like any business acquisition – several years of financials, the sale contract, the lease – plus the pharmacy-specific layer: dispense data, PBS approval, and evidence the ownership rules are satisfied in the buying entity.

Buying into a pharmacy as a partner is how much of the industry actually transitions. Because corporate consolidators legally cannot buy community pharmacies the way they buy, say, veterinary clinics, retiring owners must sell to other pharmacists – and very often the natural buyer is the pharmacist already running the dispensary. A staged buy-in, funded by a loan assessed on the pharmacy’s earnings and documented through a proper partnership or shareholders’ agreement, gives the outgoing owner a gradual exit and the incoming partner an affordable entry. The financing hinges on the buy-in valuation methodology and on drawings that genuinely service the debt, so the agreement and the loan need to be designed together.

Refinancing or refitting an existing pharmacy is the third conversation, and in 2026 it’s often the most interesting one. Owners who bought years ago frequently carry loan structures that no longer fit the business – and many are now borrowing again, this time to build out the services side of the pharmacy.

The 2026 Shift: Scope of Practice and the Consult Room

The biggest strategic change in community pharmacy right now isn’t on the shelves – it’s in the consult room. Every state and territory has been expanding what pharmacists can deliver: a broad range of vaccinations, assessment and treatment of conditions such as uncomplicated urinary tract infections, and, in several states, structured forms of pharmacist prescribing, with the details varying by jurisdiction. For the business, each new service shifts income away from pure dispensing and toward consultations – but delivering them requires private consult rooms, treatment equipment, vaccine refrigeration and trained staff.

That is, at heart, a financing question. A services refit is typically funded through a mix of fit-out finance matched to the lease term and equipment finance for the fixtures that can secure themselves, leaving working capital untouched. Lenders generally view these investments favourably when the numbers are presented properly, because services income diversifies the pharmacy away from dispensing margin – the very concentration that 60-day dispensing exposed. If you’re weighing a refit, model the service income conservatively and check what your state’s programs currently allow pharmacists to deliver, because the scope rules are still evolving state by state.

Frequently Asked Questions

Melanie McNaughton

Director & Senior Finance Broker

With years of experience in mortgage broking and finance, Melanie helps first home buyers, refinancers, investors and business owners across Geelong, the Bellarine, the Surf Coast, Melbourne and regional Victoria make their money work harder. Contact our team on 03 9020 2699.